Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCSW) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for HeartSciences (HSCSW) over the last 5 years, with Q4 2025 value amounting to $1008.0.

  • HeartSciences' Cost of Revenue fell 9896.17% to $1008.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $197940.0, marking a year-over-year decrease of 139.14%. This contributed to the annual value of $1880.0 for FY2025, which is 6908.4% down from last year.
  • Per HeartSciences' latest filing, its Cost of Revenue stood at $1008.0 for Q4 2025, which was down 9896.17% from $760.0 recorded in Q3 2025.
  • HeartSciences' Cost of Revenue's 5-year high stood at $99091.0 during Q3 2024, with a 5-year trough of $760.0 in Q1 2023.
  • For the 5-year period, HeartSciences' Cost of Revenue averaged around $19518.8, with its median value being $1520.0 (2023).
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 628690.79% in 2024, then crashed by 9923.3% in 2025.
  • Over the past 5 years, HeartSciences' Cost of Revenue (Quarter) stood at $5756.0 in 2021, then plummeted by 64.63% to $2036.0 in 2022, then decreased by 25.34% to $1520.0 in 2023, then skyrocketed by 6286.91% to $97081.0 in 2024, then tumbled by 98.96% to $1008.0 in 2025.
  • Its Cost of Revenue was $1008.0 in Q4 2025, compared to $760.0 in Q3 2025 and $97081.0 in Q4 2024.